Random Analytica

Random thoughts, charts, infographics & analysis. Not in that order

Tag: TTS

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group as at 18 July 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with two new confirmed deaths announced. Via the TGA. COVID-19 vaccine weekly safety report – 22-07-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with many vaccines.
  • Over the last week, four additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the UK case definition, one was confirmed and three were deemed probable TTS. This brings the total number of cases of TTS to 87 from 6.1 million doses of the AstraZeneca vaccine administered to date.
  • Sadly two people with confirmed TTS following the first dose of the AstraZeneca vaccine died in the last week. One was a 44-year-old man from Tasmania and the other was a 48-year-old woman from Victoria.  We extend our sincere condolences to their families and loved ones.
  • In particular, we continue to closely monitor reports of immune thrombocytopenia (ITP) and Guillain-Barre Syndrome (GBS) following vaccination with the AstraZeneca vaccine, and myocarditis and pericarditis with the Pfizer (Comirnaty) vaccine.

Simplistically put and based on the above figures you are likely to have an adverse reaction in approx. 70,100 doses (+5,100 from the previous week) and a fatal reaction in approx. 1.017-million doses (-333,000 from the previous week).

To date there have been six deaths linked to the AstraZeneca vaccine. Details:

1. 48-year old woman from NSW. Posted 16 April 2021 via the Australian Broadcasting Corporation. NSW woman’s fatal blood clotting likely linked to AstraZeneca COVID vaccine, Therapeutic Goods Administration says.

2. A 52-year old woman from NSW. Posted 10 June 2021 via the Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report – 10-06-2021.

3. A 61-year old woman from WA. Posted 8 July 2021 via the Australian Broadcasting Corporation. Death of 61-year-old WA woman last month likely linked to AstraZeneca vaccine.

4. A 72-year old woman from SA. Posted 12 July 2021 via the Australian Broadcasting Corporation. South Australian woman dies from rare blood clots after receiving AstraZeneca vaccine.

5. A 48-year old woman from Victoria. Posted 22 July 2021 via the Australian Broadcasting Corporation. TGA links deaths of 44yo Tasmanian man and 48yo Victorian woman to AstraZeneca vaccine

6. A 44-year old man from Tasmania. Posted 22 July 2021 via the Australian Broadcasting Corporation. TGA links deaths of 44yo Tasmanian man and 48yo Victorian woman to AstraZeneca vaccine

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group as at 11 July 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with one new confirmed death announced. Via the TGA. COVID-19 vaccine weekly safety report – 15-07-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • As reported by South Australian Health authorities on 12 July 2021, sadly a 72-year-old woman from South Australia has died from TTS following vaccination with a first dose of the AstraZeneca vaccine. This case was confirmed to be linked to the vaccine and was reported in last weeks’ report.
  • Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the United Kingdom (UK) case definition, four were confirmed and three were deemed probable TTS. This brings the total number of cases of TTS to 83 from 5.4 million doses administered to date.
  • We continue to closely monitor reports of immune thrombocytopenia (ITP) and Guillain-Barre Syndrome (GBS) following vaccination with the AstraZeneca vaccine and myocarditis and pericarditis with the Comirnaty vaccine.

Simplistically put and based on the above figures you are likely to have an adverse reaction in every approx. 65,000 doses (no change) and a fatal reaction in approx. every 1.350-million doses (down from 1.6-million).

To date there have been four deaths linked to the AstraZeneca vaccine. They include:

1. 48-year old woman from NSW. Posted 16 April 2021 via the Australian Broadcasting Corporation. NSW woman’s fatal blood clotting likely linked to AstraZeneca COVID vaccine, Therapeutic Goods Administration says.

2. A 52-year old woman from NSW. Posted 10 June 2021 via the Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report – 10-06-2021.

3. A 61-year old woman from WA. Posted 8 July 2021 via the Australian Broadcasting Corporation. Death of 61-year-old WA woman last month likely linked to AstraZeneca vaccine.

4. A 72-year old woman from SA. Posted 12 July 2021 via the Australian Broadcasting Corporation. South Australian woman dies from rare blood clots after receiving AstraZeneca vaccine.

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group as at 4 July 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with one new confirmed death announced. Via the TGA. COVID-19 vaccine weekly safety report – 08-07-2021. Summary:

  • The most frequently reported suspected side effects (link is external) associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • An external Vaccine Safety Investigation Group (VSIG), convened by the TGA on 2 July 2021, concluded that a very rare but fatal case of immune thrombocytopenia (ITP) in a 61-year-old woman who had received the AstraZeneca vaccine was likely to be related to immunisation.
  • Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the United Kingdom (UK) case definition, three were confirmed TTS and four were deemed probable TTS. This brings the total number of cases of TTS to 76 out of five million doses to date.

Simplistically put and based on the above figures you are likely to have an adverse reaction in every approx. 65,000 doses and a fatal reaction in approx. every 1.6-million doses.

To date there have been three deaths linked to the AstraZeneca vaccine. The latest reported fatality via the Australian Broadcasting Corporation. Death of 61-year-old WA woman last month likely linked to AstraZeneca vaccine. Excerpt:

Health authorities have concluded the death of a 61-year-old woman in hospital last month was likely linked to the AstraZeneca COVID-19 vaccine. The West Australian woman received the vaccine in early June and was admitted to Royal Perth Hospital later that month, where she died of a blood disorder.

The federal government’s Therapeutic Goods Administration (TGA) investigated the woman’s death, with an external vaccine safety investigation group of experts deeming the vaccination the likely cause. It based that conclusion on a strong lack of evidence for other causes and the timeframe within which she died after taking the vaccine.

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group as at 27 June 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with no new confirmed deaths reported. Via the TGA. COVID-19 vaccine weekly safety report – 01-07-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • Five additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the United Kingdom (UK) case definition, two were confirmed and three were deemed probable TTS. This brings the total number of cases of TTS to 69.

To date there have been approximately 4.6-million doses of AstraZeneca administered to 30 June (h/t CovidBaseAU) and two confirmed TTS deaths linked to the AstraZeneca vaccine.

It’s also worth noting that younger people are volunteering to get the AstraZeneca jab after the Prime Minister’s surprise announcement earlier this week. We should see that data flow through to next weeks report.

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) by Age Group

The Therapeutic Goods Administration (TGA) has updated its latest safety report with no new deaths reported. Via the TGA. COVID-19 vaccine weekly safety report – 24-06-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • Five additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. When assessed using the UK case definition, three were confirmed and two were deemed probable TTS. However, following reassessment of a previously reported case as being unlikely to be TTS, there is only a net increase of four cases. This brings the total number of cases of TTS to 64.
  • We are also monitoring reports of suspected myocarditis and pericarditis following vaccination with Comirnaty and suspected Guillain-Barre Syndrome following vaccination with the AstraZeneca vaccine. No causal association with either vaccine has been established at this stage.

There have been approximately 4.2-million doses of AstraZeneca administered to 21 June (h/t Jack). On 17 June 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) recommended that Pfizer’s Comirnaty vaccine be preferred over the AstraZeneca vaccine for those aged 16–60 years old. To date there have been two TTS deaths linked to the AstraZeneca vaccine meaning you have an approx. 1/2.1-million chance of dying.

Get vaccinated!

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS) to 13 June 2021

The Therapeutic Goods Administration (TGA) has updated its latest safety report with no new deaths being reported. Via the TGA. COVID-19 vaccine weekly safety report – 17-06-2021. Summary:

  • The most frequently reported suspected side effects associated with Comirnaty (Pfizer) and AstraZeneca COVID-19 vaccines continue to be events that were seen in the clinical trials, and are commonly experienced with vaccines generally.
  • Twelve additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine. The increase in the number of cases correlates with an increase in the number of doses of AstraZeneca vaccine administered during the reporting period.
  • This brings the total number of confirmed and probable TTS cases in Australia to 60. Seven of the 12 new cases occurred in individuals in aged between 50 and 59 years. When assessed using the United Kingdom (UK) case definition, three cases were confirmed and nine were deemed probable TTS.

No data was available in this report on AstraZeneca vaccines administered (in the previous week 3.3-million doses were confirmed). At the same time the Australian Technical Advisory Group on Immunisation (ATAGI) recommended the age to receive a dose be increased from 50 to 60. To date there have been two TTS deaths linked to the AstraZeneca vaccine.

Random Analytica: AstraZeneca COVID-19 vaccine and cases of Thrombosis with thrombocytopenia syndrome (TTS)

AstraZeneca is in the news this week after the Therapeutic Goods Administration (TGA) reported the death of a 52-woman from New South Wales from thrombosis with thrombocytopenia syndrome (TTS). This is the second fatality linked to the AstraZeneca vaccination roll-out following the death of a 48-year old female in April. As tragic as the deaths are there have been almost 3.3-million doses of AstraZeneca administered (to the 6th June 2021) with just 48-cases of TTS being reported to date. For context it looks like you could expect an adverse reaction resulting in death in 1 in every 1.65-million doses. According to Ian Mackay from Virology Down Under “It’s a real number. A real risk. But a very rare one”.